PENK Gene

PENK Gene

Introduction

PENK Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PENK Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PENK</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Proenkephalin</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8p11.23</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5179</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>131330</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000100644</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P01210</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>Opioid precursor proteins</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Neuropeptide precursor</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PENK (Proenkephalin)</td>
</tr>
<tr>
<td class="label">Primary peptides</td>
<td>Enkephalins</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Delta (DOR), Mu (MOR)</td>
</tr>
<tr>
<td class="label">Primary effect</td>
<td>Analgesic, anxiolytic, rewarding</td>
</tr>
<tr>
<td class="label">Stress response</td>
<td>Upregulated</td>
</tr>
<tr>
<td class="label">Brain expression</td>
<td>Widespread</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>

The PENK gene encodes proenkephalin (also called proenkephalin A), a precursor protein that is proteolytically processed to generate the enkephalin family of opioid peptides. Enkephalins are endogenous ligands for the delta opioid receptor (DOR), one of the three classical opioid receptors. Unlike the kappa opioid system (mediated by prodynorphin-derived dynorphins), the enkephalin-delta system generally produces analgesic, anxiolytic, and rewarding effects without the dysphoric properties associated with kappa activation.

In the central nervous system, enkephalins play essential roles in pain modulation, reward processing, stress responses, mood regulation, and immune function. The PENK-derived peptide family includes [Met]enkephalin, [Leu]enkephalin, [Met]enkephalin-Arg-Phe, and [Met]enkephalin-Arg-Gly-Leu. These peptides are widely distributed throughout the brain and peripheral tissues, where they act as neurotransmitters and paracrine signaling molecules.

Dysregulation of proenkephalin expression has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), depression, anxiety, and substance abuse disorders. Understanding PENK's role in these conditions provides insight into disease mechanisms and potential therapeutic targets.

Gene Overview

The PENK gene is part of the endogenous opioid peptide family, which includes proopiomelanocortin (POMC), proenkephalin (PENK), and prodynorphin (PDYN). These genes encode precursor proteins that are proteolytically processed to generate distinct sets of bioactive peptides with different receptor affinities and physiological effects.

Protein Structure and Processing

Proenkephalin Protein

Proenkephalin is a 267-amino acid precursor protein with a molecular weight of approximately 29 kDa. The protein contains multiple paired basic residues (Lys-Arg, Arg-Arg) that serve as cleavage sites for proprotein convertases:

Peptide Processing

Proenkephalin is processed in the secretory pathway by the action of several enzymes:

• Proprotein convertases: PC1/3 and PC2 cleave proenkephalin at paired basic residues.
• Carboxypeptidases: Remove basic residues from peptide intermediates.
• Peptidylglycine alpha-hydroxylating monooxygenase (PAM): Amidates the C-terminus of peptides for full biological activity.

• [Met]enkephalin (YGGFM): The predominant enkephalin; highest affinity for DOR.
• [Leu]enkephalin (YGGFL): Binds both DOR andKOR with moderate affinity.
• [Met]enkephalin-Arg-Phe (YGGFMRF): An extended peptide with biological activity.
• [Met]enkephalin-Arg-Gly-Leu (YGGFMRGL): Less abundant but active.

Trafficking and Secretion

Proenkephalin is packaged into dense-core vesicles in neurons and released in an activity-dependent manner:

• Axonal transport: Transported to synaptic terminals in vesicles.
• Activity-dependent release: Calcium-dependent exocytosis upon neuronal firing.
• Extracellular signaling: Acts on delta and mu opioid receptors on pre- and postsynaptic neurons.

Normal Function in the Brain

Pain Modulation

Enkephalins are endogenous ligands for delta and mu opioid receptors involved in pain processing:[@penk_analgesia]

• Analgesia: [Met]enkephalin and [Leu]enkephalin produce analgesic effects through DOR and MOR activation.
• Analgesic synergy: Enkephalins synergize with other analgesic systems.
• Sensory integration: DOR activation modulates sensory processing beyond pain.
• Tolerance development: Chronic DOR activation produces less tolerance than MOR activation.

Reward Processing

The proenkephalin system plays a critical role in reward and reinforcement:[@penk_reward]

• VTA and NAc: High proenkephalin expression in ventral tegmental area and nucleus accumbens.
• Dopamine interaction: Enkephalin release modulates dopamine neuron activity.
• Positive reinforcement: DOR activation produces rewarding effects.
• Natural rewards: Enkephalins mediate reward from natural stimuli (food, social interaction).

Stress Responses

The proenkephalin system is activated by stress and mediates stress-related behaviors:

• Stress-induced expression: Acute stress upregulates proenkephalin in specific brain regions.
• Anxiolytic effects: DOR activation produces anxiolytic effects, contrasting with prodynorphin's anxiogenic effects.
• Adaptive function: Enkephalin release buffers stress responses.

Mood and Emotion

Proenkephalin regulates emotional states through DOR activation:[@penk_depression]

• Antidepressant effects: DOR agonists show antidepressant-like effects in animal models.
• Anxiety reduction: DOR activation reduces anxiety-like behavior.
• Mood stabilization: Proenkephalin system may regulate mood stability.

Immune Modulation

Enkephalins have immunomodulatory effects:[@penk_inflammation]

• T-cell function: DOR expressed on T-cells; enkephalins modulate immune responses.
• Inflammation: Anti-inflammatory effects of enkephalins through DOR.
• Neuroimmune crosstalk: Enkephalins bridge neural and immune systems.

Expression Pattern

Brain Regional Distribution

Proenkephalin expression in the brain is widespread:

• Striatum: High expression in caudate nucleus and putamen (medium spiny neurons).
• Nucleus accumbens: Very high expression in shell and core.
• Hippocampus: Moderate expression in CA3 and dentate gyrus.
• Amygdala: High expression in basolateral and central nuclei.
• Hypothalamus: Expression in paraventricular and arcuate nuclei.
• Cortex: Moderate expression in cortical neurons.
• Periaqueductal gray (PAG): High expression; key for pain modulation.
• Ventral tegmental area (VTA): Expression in dopamine neurons.

Cell Type Specificity

• Medium spiny neurons: PENK in striatal GABAergic projection neurons.
• Dopaminergic neurons: Proenkephalin in VTA and substantia nigra dopamine neurons.
• Interneurons: Some cortical and hippocampal interneurons express PENK.
• Astrocytes: Lower expression in some astrocyte populations.
• Immune cells: PENK expressed in peripheral immune cells (T-cells, macrophages).

Disease Associations

Alzheimer's Disease

Proenkephalin dysregulation contributes to AD pathophysiology:

• Cholinergic interaction: Enkephalins modulate acetylcholine release in hippocampus; altered in AD.
• Amyloid effects: Amyloid-beta alters proenkephalin expression in cellular and animal models.
• Memory dysfunction: DOR activation affects memory consolidation; changes in AD.
• Synaptic plasticity: Enkephalins modulate synaptic plasticity mechanisms critical for learning.
• Stress and AD: Proenkephalin mediates stress responses that may accelerate AD pathology.

Therapeutic Implications

• DOR agonists: Selective DOR agonists show memory-enhancing effects in AD models.
• Anti-stress effects: Targeting proenkephalin-DOR signaling may reduce stress-induced pathology.
• Preclinical results: DOR activation improves cognitive function in amyloid-treated animals.

Parkinson's Disease

Proenkephalin is implicated in PD through multiple mechanisms:

• Striatal dysfunction: Altered proenkephalin expression in PD striatum.
• Dopaminergic degeneration: Enkephalin levels change in response to dopamine neuron loss.
• L-DOPA-induced dyskinesia: Altered proenkephalin in models of dyskinesia.
• Motor control: Enkephalins in basal ganglia influence motor function.
• Neuroprotection: DOR activation may protect dopaminergic neurons.

Evidence from Studies

• Post-mortem studies: Altered proenkephalin levels in PD substantia nigra and striatum.
• Animal models: 6-OHDA lesions alter striatal proenkephalin expression.
• Therapeutic potential: DOR agonists show neuroprotective effects in PD models.

Huntington's Disease

Proenkephalin dysregulation in HD:

• Striatal medium spiny neurons: Early upregulation of proenkephalin in HD.
• Disease progression: Proenkephalin changes correlate with disease severity.
• Motor symptoms: Contributes to movement abnormalities in HD.

Psychiatric Disorders

Depression

• Altered expression: Proenkephalin mRNA changes in depression models and patient tissue.
• DOR dysfunction: The proenkephalin-DOR system is dysregulated in depressive states.
• Therapeutic targets: DOR agonists show antidepressant effects in clinical trials.
• Mechanism: DOR activation produces rapid antidepressant effects.

Anxiety

• Anxiolytic effects: DOR activation reduces anxiety-like behavior.
• Stress-induced anxiety: Proenkephalin buffers stress-induced anxiety.
• Genetic studies: PENK polymorphisms associated with anxiety disorders.

Addiction

• Reward processing: Enkephalins mediate reward from drugs of abuse.
• Withdrawal: Altered proenkephalin during opioid withdrawal.
• Relapse: DOR antagonists reduce drug-seeking in animal models.

Other Conditions

• Epilepsy: Proenkephalin altered in seizure models; DOR modulators show anticonvulsant effects.
• Migraine: Enkephalins implicated in migraine pathophysiology.
• Chronic pain: Proenkephalin in endogenous pain modulation systems.

Molecular Interactions

Receptor Interactions

Enkephalins act primarily on delta and mu opioid receptors:

• Delta opioid receptor (DOR): Primary high-affinity receptor for enkephalins; GPCR coupled to Gi/o proteins.
• Mu opioid receptor (MOR): Lower affinity for enkephalins; mediates analgesia and reward.
• Kappa opioid receptor (KOR): Very low affinity for enkephalins.

Signaling Pathways

DOR activation triggers multiple intracellular cascades:

Downstream Effects

DOR activation produces:

• Reduced neurotransmitter release: Presynaptic inhibition of glutamate and other transmitters.
• Hyperpolarization: Postsynaptic K⁺ channel activation.
• Transcription regulation: Gene expression changes through MAPK pathways.
• Plasticity changes: Long-term changes in synaptic strength.
• Anti-anxiety effects: Anxiolytic signaling through specific pathways.

Genetic Variations and Polymorphisms

Single Nucleotide Polymorphisms

Several PENK polymorphisms have been associated with disease and behavior:

• rs3138520: Promoter polymorphism; affects stress-induced expression.
• rs2239775: 3' UTR variant; associated with substance use disorders.
• rs3751621: Intron variant; linked to depression susceptibility.
• rs2873164: Coding variant with potential functional consequences.

Copy Number Variations

• CNV duplications: Rare duplications encompassing PENK may alter function.
• Deletions: PENK deletions associated with specific phenotypes.

Epigenetic Regulation

• DNA methylation: PENK promoter methylation correlates with stress exposure.
• Histone modifications: H3K4me3 changes at PENK locus with behavior.
• Environmental interactions: Epigenetic changes mediate environmental effects on PENK expression.

Comparison with Other Opioid Precursors

The three opioid precursor systems have distinct but overlapping functions in pain, reward, and stress.

Therapeutic Implications

Drug Development

Targeting the proenkephalin-DOR system:

• DOR agonists: Selective DOR agonists (DPDPE, deltorphin) and clinically used compounds.
• Bias signaling: G protein-biased DOR ligands with improved therapeutic profiles.
• Peripherally restricted: Compounds that target peripheral DOR for pain without central effects.

Clinical Applications

• Chronic pain: DOR agonists produce analgesia without MOR-associated tolerance and dependence.
• Depression: DOR agonists show rapid antidepressant effects in clinical trials.
• Anxiety: DOR blockade produces anxiolytic effects.
• Parkinson's disease: DOR agonists may provide neuroprotection.
• Addiction: DOR modulators reduce drug-seeking behavior.

Biomarker Potential

• CSF met-enkephalin: Measurable in cerebrospinal fluid.
• Gene expression: PENK mRNA as peripheral biomarker.
• Genetic testing: PENK variants for risk stratification.

Animal Models and Experimental Findings

Transgenic Mouse Models

• PENK knockout mice: Show altered pain sensitivity, stress responses, and reward processing.
• PENK overexpressing mice: Display enhanced DOR signaling, analgesic phenotypes.
• Conditional knockouts: Brain-region specific deletions reveal region-dependent functions.

Pharmacological Studies

• DOR agonists: Selective agonists (DPDPE, deltorphin II, SNC80) show effects in models.
• DOR antagonists: Naltrindole and other antagonists used to study DOR blockade effects.
• Bias agonists: G protein-biased ligands with novel therapeutic potential.

Behavioral Paradigms

• Hot plate test: PENK affects pain response latencies.
• Conditioned place preference: Enkephalins produce rewarding states.
• Forced swim test: DOR agonists have antidepressant-like effects.
• Elevated plus maze: DOR activation reduces anxiety-like behavior.

Cross-Links

• [PENK Protein](/proteins/penk-protein)
• [Delta Opioid Receptor](/proteins/delta-opioid-receptor)
• [Mu Opioid Receptor](/proteins/mu-opioid-receptor)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Huntington's Disease](/diseases/huntington-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-neurodegeneration)
• [Dopamine Signaling](/mechanisms/dopamine-signaling-parkinsons)
• [Opioid System](/mechanisms/opioid-system-neurodegeneration)
• [Stress Response](/mechanisms/stress-response-neurodegeneration)

See Also

• [Enkephalin Peptides](/proteins/enkephalin-peptides)
• [Opioid System](/mechanisms/opioid-system-neurodegeneration)
• [Pain Modulation](/mechanisms/pain-modulation-neurodegeneration)

External Links

• [NCBI Gene: PENK](https://www.ncbi.nlm.nih.gov/gene/5179)
• [UniProt: P01210](https://www.uniprot.org/uniprot/P01210)
• [OMIM: 131330](https://www.omim.org/entry/131330)
• [Ensembl: ENSG00000100644](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100644)
• [IUPHAR: DOR](https://www.guidetopharmacology.org/GTORecord?q=Delta%20opioid%20receptor)

Conclusion

Proenkephalin (PENK) is a neuropeptide precursor that gives rise to the enkephalin family of delta opioid receptor ligands. The proenkephalin-DOR system plays critical roles in pain modulation, reward processing, stress responses, and mood regulation. Dysregulation of this system contributes to Alzheimer's disease, Parkinson's disease, depression, anxiety, and addiction. Targeting the proenkephalin-DOR pathway with delta opioid receptor agonists represents a promising therapeutic strategy for multiple neurological and psychiatric disorders. Unlike the kappa opioid system (prodynorphin-dynorphin) which produces dysphoric effects, the enkephalin-delta system offers analgesic and anxiolytic benefits without the severe side effects associated with mu opioid activation. Continued research on PENK biology will advance understanding of neurodegeneration and potentially lead to novel treatments.

References

[TEST_MARKER_12345]

Pathway Diagram

The following diagram shows the key molecular relationships involving PENK Gene discovered through SciDEX knowledge graph analysis: